Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5AP | P20292 | 3/20 | 0.41 |
| ▸ | FEN1 | P39748 | 1/20 | 0.41 |
| ▸ | F2RL3 | Q96RI0 | 4/20 | 0.40 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.37 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.37 |
| ▸ | FPR3 | P25089 | 1/20 | 0.36 |
| ▸ | FPR2 | P25090 | 1/20 | 0.36 |
| ▸ | KDM1A | O60341 | 1/20 | 0.35 |
| ▸ | PDE8B | O95263 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28670059 | 1.00 | ALOX5AP (0.41) | ALOX5APFEN1F2RL3IRAK4GPR119 | |
| SCHEMBL19046026 | 1.00 | ALOX5AP (0.41) | ALOX5APFEN1F2RL3IRAK4GPR119 | |
| SCHEMBL20531369 | 0.88 | IRAK4 (0.44) | IRAK4 | |
| SCHEMBL20531370 | 0.88 | IRAK4 (0.44) | IRAK4 | |
| SCHEMBL19046025 | 0.88 | F2RL3 (0.39) | ALOX5APFEN1F2RL3IRAK4GPR119 | |
| SCHEMBL28663618 | 0.86 | F2RL3 (0.38) | ALOX5APFEN1F2RL3IRAK4GPR119 | |
| SCHEMBL28663614 | 0.86 | F2RL3 (0.38) | ALOX5APFEN1F2RL3IRAK4GPR119 | |
| SCHEMBL28663720 | 0.77 | IRAK4 (0.59) | IRAK4 | |
| SCHEMBL14431420 | 0.74 | ALOX5AP (0.48) | ALOX5APFEN1F2RL3 | |
| SCHEMBL448827 | 0.74 | ALOX5AP (0.47) | ALOX5APFEN1F2RL3GPR119FPR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220332718-A1 | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | GENENTECH, INC. (US) | 2022-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220332718-A1 | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | IRAK1, IRAK4, IRAK2 | ALOX5AP 2805/4885FEN1 512/4885F2RL3 1048/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.